ClinicalTrials.gov
public full text
Public Domain
Gadopiclenol in Contrast Enhanced MRI of the Prostate
The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant prostate cancer on Prostate MRI, as categorized by the PI-RADS v2 classification categories.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems#892093
- Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer#1212010
- Development and Optimization of Gadolinum-Based Lipid Nanoparticles for Lymphatic MRI#1067943
- Development and Optimization of Gadolinum-Based Lipid Nanoparticles for Lymphatic MRI#1067932
- Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand#871461
Record · ID 1349829
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive